Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SENS-401 PK and Safety in Healthy Subjects
NCT03071003Phase 1Completed
- Sponsor
- Simbec-Orion
- Start
- Oct 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of arazasetron besylate in inner ear disorder (3 cohorts), sponsored by Simbec-Orion. Primary endpoint: Safety of SENS 401 after multiple doses at 4 weeks. Started Oct 2016; status: completed.
02
Drugs
arazasetron besylate
03
Conditions
inner ear disorder
Beyond the preview
Go deeper on NCT03071003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03071003.